Synthesis, antimicrobial evaluation and in silico studies of novel 3,4-disubstituted pyrrolidinesulfonamides
Abstract
3,4-Disubstituted pyrrolidinesulfonamides were synthesized and screened for their antimicrobial activity. Title compounds were established as potent antibacterial and antifungal agents. Noteworthy antimicrobial activity was found for the title compounds against the tested microorganisms. They exhibit comparable results with standard drugs. Besides the in vitro antimicrobial activity, the synthesized compounds were evaluated for their in silico inhibitory activity on active site of β-glucosidase enzyme. In silico studies were done by GOLD docking method against β-glucosidase 3VKK (PDB Id). In silico studies were conducted to evaluate the ability of synthesized compounds to inhibit the β-glucosidase enzyme. The results revealed that 3,4-disubstitutedpyrrolidinesulfonamides are the potent β-glucosidase inhibitors by binding at the active site. A sensible inhibition against β-glucosidases was observed for the compound with 13,4-oxadizole ring has higher β-glucosidase inhibition activity than the other compounds. The free energy of binding and inhibition constant (Ki) of the docked compounds were evaluated and presented.
References
2 Blum A, Diederich WE (2009) Curr Org Synth 6:38-53. Crossref
3 Najera C, Sansano JM (2013) Recherche et développement Grand prix SCF January 370
4 Hensler ME, Bernstein G, Nizet V, Nefzib A (2006) Bioorg Med Chem Lett 16(19):5073-5079. Crossref
5 (2006) Patent US7115639 B2 Pyrrolidineoxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists: Schwarz M, Quattropani A, Page P, Thomas RJ, Pomel V.
6 Sharma R, Soman SS (2015) Eur J Med Chem 90:342-350. Crossref
7 Supuran CT, Casini A, Scozzafava A (2003) Med Res Rev 23(5):535-558. Crossref
8 Roush WR, Gwaltney SL, Cheng J, Scheidt KA, McKerrow GH, Hansell E (1998) J Am Chem Soc 120(42)10994-10995. Crossref
9 Thaisrivongs S, Skulnick HI, Turner SR, Strohbach JW, Tommasi RA, et al (1996) J Med Chem 39(22)4349-4353. Crossref
10 Supuran CT, Casini A, Scozzafava A (2003) Med Res Rev 23(5):535-558. Crossref
11 Koyanagi N, Nagasu T, Fujita F (1994) Cancer Res 1(54)1702-1706.
12 Werner LH, Habicht E, Zergenyi J (1978) Sulfonamide diuretics in Diuretic agents (ed. by Cragoe EJ). American Chemical Society, Washington, DC. P.38-55.
13 Yin Z, Zhang W, Feng F, Zhang Y, Kang W (2014) Food Science and Human Wellness 3(3-4)136-174. Crossref
14 Supuran CT, Innocenti A, Mastrolorenzo A, Scozzafava A (2004) Mini-Reviews in Medicinal Chemistry 4(2)189-200. Crossref
15 Blass BE, Iyer P, Abou-Gharbia M, Childers WE, Gordon JC, et al (2016) Bioorg Med Chem Lett 26(23)5825-5829. Crossref
16 Sánchez-Medina A, Garcia-Sosa K, May-Pat F, Pea-Rodríguez LM (2001) Phytomedicine 8(2):144-151. Crossref
17 De Melo EB, Gomes AS, Carvalho I (2006) Tetrahedron 62(44)10277-10302. Crossref
18 Cheng AYY, Josse RG (2004) Drug Discov Today: Therapeutic Strategies 1(2)201-206. Crossref
19 Von Geldern TV, Tasker AS, Sorensen BK, Winn M, Szczepankiewicz BG, et al (1999) J Med Chem 42(18):3668-3678. Crossref
20 Papandréou MJ, Barbouche R, Guieu R, Kieny MP, Fenouillet E (2002) Mol Pharmacol 61(1):186-193. Crossref
21 Nishimura Y (2003) Curr Top Med Chem 3(5):575-591. Crossref
22 Santosh Kumar B, Raghavendra Guru Prasad A, Madhu G, Raveendra Reddy P, Ravindranath LK (2014) Ann Pharm Fr 72:256-266. Crossref
23 Da Silva ET, Fona FS, Lima ELS (2004) J Braz Chem Soc 15(3):433-436. Crossref
24 Chen HH, Gross S, Liao J, McLaughlin M, Dean T, Sly WS, May JA (2000) Bioorg Med Chem 8: 957-975. Crossref
25 Santosh Kumar B, Madhu G, Raveendra Reddy P, Ravindranath LK (2012) Der Chemical Sinica 3(5):1124-1134.
26 Hui A, Zhang J, Sun H, Wang Z (2008) ARKIVOC (ii)25-32.
27 Lysek R, Vogel P (2004) Helv Chim Acta 87(12)3167-3181. Crossref
28 Popowycz F, Gerber-Lemaire S, Schutz C, Vogel P (2004) Helv Chim Acta 87(4)800-180. Crossref
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-NC-ND 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.